Core Points - The Shenzhen-Hong Kong Stock Connect Medical Index (983036) closed at 4327.65 points, down 0.28%, with a trading volume of HKD 7.682 billion and a turnover rate of 0.9% [1] - Among the index constituents, 21 stocks rose while 36 stocks fell, with Kewei Medical leading the gainers at a 4.14% increase and Xianjian Technology leading the decliners at a 9.14% decrease [1] Index Constituents Summary - The top ten constituents of the Shenzhen-Hong Kong Stock Connect Medical Index include: - Mindray Medical (sz300760) with a weight of 14.56%, latest price at HKD 198.00, and a market cap of HKD 240.063 billion, down 0.36% [1] - Yier Eye Hospital (sz300015) with a weight of 11.62%, latest price at HKD 11.23, and a market cap of HKD 104.724 billion, down 0.62% [1] - Lejin Medical (sz300003) with a weight of 4.85%, latest price at HKD 15.64, and a market cap of HKD 28.831 billion, down 0.64% [1] - Aimeike (sz300896) with a weight of 4.80%, latest price at HKD 143.25, and a market cap of HKD 43.346 billion, up 1.47% [1] - Yuyue Medical (sz002223) with a weight of 4.66%, latest price at HKD 35.68, and a market cap of HKD 35.768 billion, up 0.17% [1] - Yingke Medical (sz300677) with a weight of 3.64%, latest price at HKD 41.76, and a market cap of HKD 27.360 billion, down 0.17% [1] - Furuijia (sz300049) with a weight of 3.59%, latest price at HKD 69.33, and a market cap of HKD 18.371 billion, down 0.82% [1] - Meinian Health (sz002044) with a weight of 3.58%, latest price at HKD 5.09, and a market cap of HKD 19.924 billion, up 0.39% [1] - Sinopharm Holdings (hk01099) with a weight of 3.35%, latest price at HKD 18.15, and a market cap of HKD 56.638 billion, down 0.40% [1] - Ping An Good Doctor (hk01833) with a weight of 2.63%, latest price at HKD 12.23, and a market cap of HKD 26.434 billion, down 3.24% [1] Capital Flow Analysis - The index constituents experienced a net outflow of HKD 382 million from institutional investors, while retail investors saw a net inflow of HKD 329 million [1] - Notable individual stock capital flows include: - Meinian Health (sz002044) with a net inflow of HKD 23.6308 million from institutional investors [2] - Aimeike (sz300896) with a net inflow of HKD 5.8353 million from institutional investors [2] - Yier Eye Hospital (sz300015) with a net outflow of HKD 20.7620 million from retail investors [2]

证券之星消息，截至2025年12月8日收盘，开立医疗(300633)报收于27.22元，上涨1.04%，换手率 0.61%，成交量2.64万手，成交额7179.33万元。 12月8日的资金流向数据方面，主力资金净流入665.36万元，占总成交额9.27%，游资资金净流出657.32 万元，占总成交额9.16%，散户资金净流出8.04万元，占总成交额0.11%。 近5日资金流向一览见下表： | | | | | 日期 收盘价 涨跌幅 主力净流入 主力净占比 游资净点比 散户净流入 散户净占比 | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 2025-12-08 | 27.22 | 1.04% | 665.36万 | 9.27% | -657.32万 | -9.16% | -8.04万 | -0.11% | | 2025-12-05 | 26.94 | 0.79% | ● 12.41万 | 0.20% | -78.63万 | -1.27% | 66.22万 | 1.07% | | 2025-12-04 | 26.73 | -1. ...

最新公告列表 截至2025年12月8日收盘，开立医疗（300633）报收于27.22元，较前一交易日上涨1.04%，最新总市值 为117.78亿元。该股当日开盘26.92元，最高27.39元，最低26.92元，成交额达7179.33万元，换手率为 0.61%。 公司近日发布公告称，深圳开立生物医疗科技股份有限公司于2025年12月4日召开2025年员工持股计划 第一次持有人会议，审议通过设立员工持股计划管理委员会，并选举冯乃章为管理委员会主任，李翔、 罗曰佐为委员。管理委员会将代表持股计划行使股东权利并负责日常管理。会议还通过了授权管理委员 会办理持股计划相关事宜的议案，授权范围包括召集持有人会议、资产管理、权益分配等。表决结果均 为100%同意，无反对或弃权。 《2025年员工持股计划第一次持有人会议决议公告》 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 ...

证券之星消息，截至2025年12月5日收盘，开立医疗(300633)报收于26.94元，上涨0.79%，换手率 0.54%，成交量2.32万手，成交额6190.42万元。 | 指标 | 开立医疗 | 医疗器械行业均值 | 行业排名 | | --- | --- | --- | --- | | 总市值 | 116.57亿元 | 110.35亿元 | 27 124 | | 净资产 | 31.19亿元 | 39.1亿元 | 46 124 | | 净利润 | 3351.11万元 | 2.12亿元 | 74 124 | | 市盈率(动) | 260.9 | 64.34 | 87 124 | | 市净率 | 3.74 | 3.85 | 90 124 | | 毛利率 | 60.36% | 51.22% | 50 124 | | 净利率 | 2.3% | 9.57% | 88 124 | | ROE | 1.07% | 0.15% | 84 124 | 开立医疗2025年三季报显示，前三季度公司主营收入14.59亿元，同比上升4.37%；归母净利润3351.11 万元，同比下降69.25%；扣非净利润2399.1万元，同比下降 ...

证券代码：300633 证券简称：开立医疗 公告编号：2025-051 深圳开立生物医疗科技股份有限公司 2025 年员工持股计划第一次持有人会议决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 一、持有人会议召开情况 深圳开立生物医疗科技股份有限公司（以下简称"公司"）2025 年员工持股 计划（以下简称"本持股计划"）第一次持有人会议于 2025 年 12 月 4 日在公司 会议室以现场及通讯会议方式召开，本次会议由公司董事会秘书李浩先生召集并 主持，会议应出席持有人 7 名，实际出席持有人 7 名，出席持有人代表本持股计 划份额对应的标的股票数量为 50 万股，占公司 2025 年员工持股计划持有标的股 票总数的 100%。本次会议的召集、召开和表决程序符合相关法律、法规、规范 性文件及公司 2025 年员工持股计划的相关规定。 二、会议审议情况 1、审议通过《关于设立公司 2025 年员工持股计划管理委员会的议案》 为确保公司 2025 年员工持股计划的顺利实施，根据《2025 年员工持股计划 （草案）》、《2025 年员工持股计划管理办法》等 ...

近5日资金流向一览见下表： | 日期 | | | | | 收盘价 涨跌幅 主力净流入 主力净占比 游资净占比 散户净流入 散户净点比 | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 2025-12-04 | 26.73 | -1.00% | 457.28万 | 6.85% | -207.81万 | -3.11% | -249.47万 | -3.74% | | 2025-12-03 | | 27.00 -0.18% | · 120.01万 | 1.68% | 46.08万 | 0.64% | -166.09万 | -2.32% | | 2025-12-02 | 27.05 | -2.17% | 338.75万 | 3.28% | -916.07万 | -8.87% | 577.32万 | 5.59% | | 2025-12-01 | 27.65 | 0.04% | 236.63万 | 2.69% | -34.11万 | -0.39% | -202.52万 | -2.30% | | 2025-11-28 | 27.64 | 0.7 ...

Core Insights - The medical device distribution industry is facing significant challenges due to the expansion of centralized procurement, which has intensified price competition and reduced profit margins for distributors [2][3][4][5]. Group 1: Industry Trends - Centralized procurement for medical devices began in 2020 in Anhui and Fujian, but has recently expanded to most provinces in China, leading to a significant shift in the market landscape [2][10]. - The prices of major medical devices have drastically decreased, with examples including digital X-ray (DR) prices dropping from over 1 million to 200,000, and CT prices falling to historical lows of 600,000 [3][9]. - The ongoing anti-corruption campaign in the medical sector has heightened scrutiny on procurement practices, contributing to the rapid expansion of centralized procurement initiatives [3][12]. Group 2: Distributor Challenges - Many medical device distributors are considering transitioning to other business models, such as focusing on devices that are not yet subject to centralized procurement or moving upstream to manufacturing [4][5]. - The profit margins for distributors have significantly decreased, with some reporting earnings dropping from several million to only tens of thousands due to the competitive bidding process [4][5]. - It is projected that only about 10% of current medical device distributors will remain in the industry post-procurement expansion, primarily focusing on after-sales services [5][8]. Group 3: Manufacturer Responses - Major international manufacturers like GE and Philips are experiencing market share losses due to intensified competition from local companies, which are increasingly winning bids in centralized procurement [6][8]. - Local companies such as Wandong Medical and Mindray have shown strong performance in procurement bids, with Wandong achieving a 47% bid success rate for CT devices [8][9]. - Despite the increased competition, some manufacturers like United Imaging have managed to grow their revenue and profits, indicating that innovation may provide a competitive edge in this challenging environment [9]. Group 4: Future Outlook - The trend of centralized procurement is expected to continue expanding across provinces, with most regions likely to implement such measures within the next 3 to 5 years [12]. - The complexity of nationwide centralized procurement is acknowledged, with regional differences in medical device usage making it more feasible to conduct procurement at the provincial level [12].

Core Viewpoint - The stock of Kaili Medical (300633) has shown a slight decline in price, with recent financial data indicating mixed performance in terms of revenue and profit margins [1][3]. Financial Performance - As of December 3, 2025, the closing price of Kaili Medical was 27.0 yuan, down by 0.18% with a trading volume of 26,600 shares and a total transaction value of 71.54 million yuan [1]. - In the past three quarters, the company reported a total revenue of 1.459 billion yuan, a year-on-year increase of 4.37%, while the net profit attributable to shareholders was 33.51 million yuan, a significant decline of 69.25% [3]. - The third quarter of 2025 saw a single-quarter revenue of 495 million yuan, up 28.42% year-on-year, but a net loss of 13.52 million yuan, despite a year-on-year increase of 78.05% [3]. Market Position and Ratios - Kaili Medical's total market capitalization is 11.683 billion yuan, slightly above the industry average of 11.01 billion yuan, ranking 28th out of 124 in the medical device sector [3]. - Key financial ratios include a price-to-earnings (P/E) ratio of 261.48, significantly higher than the industry average of 60.46, indicating a potential overvaluation [3]. - The company has a gross margin of 60.36%, which is above the industry average of 51.22%, but its net profit margin is only 2.3%, compared to the industry average of 9.57% [3]. Investment Sentiment - Over the last 90 days, 16 institutions have rated the stock, with 11 buy ratings and 5 hold ratings, suggesting a generally positive outlook among analysts [4]. - The average target price set by institutions for Kaili Medical is 40.07 yuan, indicating potential upside from the current trading price [4].

12月2日的资金流向数据方面，主力资金净流入338.75万元，占总成交额3.28%，游资资金净流出916.07 万元，占总成交额8.87%，散户资金净流入577.32万元，占总成交额5.59%。 近5日资金流向一览见下表： | | | | | 日期 收盘价 涨跌幅 主力净流入 主力净占比 游资净点比 散户净流入 散户净占比 | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 2025-12-02 | 27.05 | -2.17% | 338.75万 | 3.28% | -916.07万 | -8.87% | 577.32万 | 5.59% | | 2025-12-01 | | 27.65 0.04% | 236.63万 | 2.69% | -34.11万 | -0.39% | -202.52万 | -2.30% | | 2025-11-28 | | 27.64 0.77% | -241.90万 | -4.37% | 238.63万 | 4.31% | 3.27万 | 0.06% | | 2025-11-27 | 27.43 | ...

证券之星消息，截至2025年12月1日收盘，开立医疗(300633)报收于27.65元，上涨0.04%，换手率 0.74%，成交量3.18万手，成交额8797.56万元。 12月1日的资金流向数据方面，主力资金净流入236.63万元，占总成交额2.69%，游资资金净流出34.11 万元，占总成交额0.39%，散户资金净流出202.52万元，占总成交额2.3%。 近5日资金流向一览见下表： | | | | | 日期 收盘价 涨跌幅 主力净流入 主力净占比 游资净齿比 散户净流入 散户净占比 | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 2025-12-01 | 27.65 | 0.04% | 236.63万 | 2.69% | -34.11万 | -0.39% | -202.52万 | -2.30% | | 2025-11-28 | | 27.64 0.77% | -241.90万 | -4.37% | 238.63万 | 4.31% | _ 3.27万 | 0.06% | | 2025-11-27 | | 27.43 0 ...